Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Current Assets (2019 - 2025)

Eton Pharmaceuticals' Current Assets history spans 7 years, with the latest figure at $72.0 million for Q3 2025.

  • For Q3 2025, Current Assets rose 142.02% year-over-year to $72.0 million; the TTM value through Sep 2025 reached $72.0 million, up 142.02%, while the annual FY2024 figure was $41.0 million, 52.84% up from the prior year.
  • Current Assets for Q3 2025 was $72.0 million at Eton Pharmaceuticals, up from $68.4 million in the prior quarter.
  • Across five years, Current Assets topped out at $72.0 million in Q3 2025 and bottomed at $16.4 million in Q3 2022.
  • The 5-year median for Current Assets is $26.3 million (2023), against an average of $31.3 million.
  • The largest annual shift saw Current Assets crashed 38.06% in 2022 before it skyrocketed 169.1% in 2025.
  • A 5-year view of Current Assets shows it stood at $23.6 million in 2021, then fell by 15.25% to $20.0 million in 2022, then surged by 34.17% to $26.8 million in 2023, then surged by 52.84% to $41.0 million in 2024, then surged by 75.52% to $72.0 million in 2025.
  • Per Business Quant, the three most recent readings for ETON's Current Assets are $72.0 million (Q3 2025), $68.4 million (Q2 2025), and $50.0 million (Q1 2025).